Literature DB >> 33755232

WhiMSICAL: A global Waldenström's Macroglobulinemia patient-derived data registry capturing treatment and quality of life outcomes.

Ibrahim Tohidi-Esfahani1,2, Andrew Warden3, Elena Malunis4, Peter L DeNardis4, Javier Haurat5,6, Marita Black5,6, Stephen Opat7,8, Damien Kee9,10,11, Shirley D'Sa12, Marie José Kersten13, Ruth L Spearing14,15, Maria Lia Palomba16,17, Adam J Olszewski18,19, Carl Harrington4, Clare L Scott6,9,20, Judith Trotman1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33755232     DOI： 10.1002/ajh.26173

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  3 in total

Review 1.  Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies.

Authors:  Gita Thanarajasingam; Lori M Minasian; Vishal Bhatnagar; Franco Cavalli; R Angelo De Claro; Amylou C Dueck; Tarec C El-Galaly; Neil Everest; Jan Geissler; Christian Gisselbrecht; Nicole Gormley; John Gribben; Mary Horowitz; S Percy Ivy; Caron A Jacobson; Armand Keating; Paul G Kluetz; Yok Lam Kwong; Richard F Little; Matthew J Matasar; Maria-Victoria Mateos; Kristen McCullough; Robert S Miller; Mohamad Mohty; Philippe Moreau; Lindsay M Morton; Sumimasa Nagai; Abhilasha Nair; Loretta Nastoupil; Kaye Robertson; Surbhi Sidana; Karin E Smedby; Pieter Sonneveld; Kyriaki Tzogani; Flora E van Leeuwen; Galina Velikova; Diego Villa; John R Wingard; John F Seymour; Thomas M Habermann
Journal:  Lancet Haematol       Date:  2022-05       Impact factor: 30.153

Review 2.  Treatment paradigm in Waldenström macroglobulinemia: frontline therapy and beyond.

Authors:  Saurabh Zanwar; Jithma P Abeykoon
Journal:  Ther Adv Hematol       Date:  2022-04-29

3.  Two-year outcomes of tirabrutinib monotherapy in Waldenström's macroglobulinemia.

Authors:  Naohiro Sekiguchi; Shinya Rai; Wataru Munakata; Kenshi Suzuki; Hiroshi Handa; Hirohiko Shibayama; Tomoyuki Endo; Yasuhito Terui; Noriko Iwaki; Noriko Fukuhara; Hiro Tatetsu; Shinsuke Iida; Takayuki Ishikawa; Daisuke Iguchi; Koji Izutsu
Journal:  Cancer Sci       Date:  2022-04-06       Impact factor: 6.518
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.